Literature DB >> 11527672

Cancer cachexia and its treatment with fish-oil-enriched nutritional supplementation.

M D Barber1.   

Abstract

OBJECTIVE: Cachexia is a common condition affecting those with advanced cancer. This review explores mechanisms of cachexia and possible treatments devised with these mechanisms in mind.
METHODS: Selective review of the relevant scientific literature was performed with particular emphasis on studies performed by our group over the past 10 y involving patients with advanced pancreatic cancer.
RESULTS: Cancer cachexia adversely affects patient quality of life and survival. It is characterized by a lack of a normal anabolic response to the provision of apparently adequate nutrition. It appears to result from a persistent response to illness stimulated by the cancer resulting in a proinflammatory cytokine and catabolic hormonal environment. Interventions that ignore this inflammatory milieu have had little success. More promising interventions have a broad antiinflammatory component such as nonsteroidal antiinflammatory drugs or fish oil. Preliminary studies of a combination of fish oil as an antiinflammatory agent with nutritional supplementation show promise in reversing weight loss with apparent gains in lean tissue and performance status in association with normalization of the metabolic environment in patients with advanced pancreatic cancer.
CONCLUSIONS: Cancer cachexia produces a metabolic environment that prevents the appropriate use of supplied nutrition. Antiinflammatory agents such as fish oil in combination with nutritional supplementation may reverse aspects of cachexia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11527672     DOI: 10.1016/s0899-9007(01)00631-1

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  8 in total

1.  New perspective for nutritional support of cancer patients: Enteral/parenteral nutrition.

Authors:  Gamze Akbulut
Journal:  Exp Ther Med       Date:  2011-04-01       Impact factor: 2.447

2.  Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.

Authors:  J N Gordon; T M Trebble; R D Ellis; H D Duncan; T Johns; P M Goggin
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

3.  Nutrition intervention: a strategy against systemic inflammatory syndrome.

Authors:  Helieh S Oz; Theresa S Chen; Manuela Neuman
Journal:  JPEN J Parenter Enteral Nutr       Date:  2009-04-14       Impact factor: 4.016

4.  Eicosapentaenoic acid and oxypurinol in the treatment of muscle wasting in a mouse model of cancer cachexia.

Authors:  Vanessa C Vaughan; Melanie Sullivan-Gunn; Edward Hinch; Peter Martin; Paul A Lewandowski
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

5.  Cancer cachexia: impact, mechanisms and emerging treatments.

Authors:  Vanessa C Vaughan; Peter Martin; Paul A Lewandowski
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-10-25       Impact factor: 12.910

6.  The response of leptin, interleukin-6 and fat oxidation to feeding in weight-losing patients with pancreatic cancer.

Authors:  M D Barber; D C McMillan; A M Wallace; J A Ross; T Preston; K C H Fearon
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

7.  Plasma and neutrophil fatty acid composition in advanced cancer patients and response to fish oil supplementation.

Authors:  V C Pratt; S Watanabe; E Bruera; J Mackey; M T Clandinin; V E Baracos; C J Field
Journal:  Br J Cancer       Date:  2002-12-02       Impact factor: 7.640

8.  Nutritional Effect of Oral Supplement Enriched in ω-3 Fatty Acids, Arginine, RNA on Immune Response and Leukocyte-platelet Aggregate Formation in Patients Undergoing Cardiac Surgery.

Authors:  Harunobu Iwase; Hiroko Kariyazono; Junko Arima; Hiroyuki Yamamoto; Kazuo Nakamura
Journal:  Nutr Metab Insights       Date:  2014-05-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.